Vertex Pharmaceuticals Inc. (VRTX) Given a $109.00 Price Target by Stifel Nicolaus Analysts
Other research analysts have also issued research reports about the company. Vetr raised Vertex Pharmaceuticals from a hold rating to a buy rating and set a $94.38 price objective for the company in a report on Monday, June 13th. Zacks Investment Research raised Vertex Pharmaceuticals from a hold rating to a buy rating and set a $98.00 target price for the company in a research note on Wednesday, July 20th. Piper Jaffray Cos. reaffirmed a buy rating on shares of Vertex Pharmaceuticals in a research note on Saturday, June 18th. Jefferies Group reaffirmed a buy rating and issued a $103.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, June 17th. Finally, Credit Suisse Group AG reaffirmed a buy rating on shares of Vertex Pharmaceuticals in a research note on Thursday, June 16th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Vertex Pharmaceuticals currently has an average rating of Buy and a consensus target price of $118.36.
Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 2.09% during midday trading on Thursday, hitting $86.78. 776,997 shares of the stock were exchanged. The company’s 50 day moving average is $95.19 and its 200 day moving average is $89.63. Vertex Pharmaceuticals has a 1-year low of $75.90 and a 1-year high of $134.71. The company’s market capitalization is $21.50 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.03. Vertex Pharmaceuticals had a negative return on equity of 12.34% and a negative net margin of 17.77%. The company earned $431.61 million during the quarter, compared to analyst estimates of $428.08 million. During the same quarter in the previous year, the firm earned ($0.54) earnings per share. Vertex Pharmaceuticals’s revenue was up 159.9% on a year-over-year basis. Analysts predict that Vertex Pharmaceuticals will post $0.98 earnings per share for the current fiscal year.
In related news, Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $88.81, for a total transaction of $577,265.00. Following the completion of the transaction, the director now owns 274,725 shares in the company, valued at approximately $24,398,327.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Joshua S. Boger sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $100.46, for a total value of $753,450.00. Following the transaction, the director now owns 274,725 shares of the company’s stock, valued at approximately $27,598,873.50. The disclosure for this sale can be found here. Corporate insiders own 1.90% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Capstone Asset Management Co. boosted its position in Vertex Pharmaceuticals by 4.2% in the first quarter. Capstone Asset Management Co. now owns 23,001 shares of the pharmaceutical company’s stock worth $1,828,000 after buying an additional 930 shares during the last quarter. Commonwealth Equity Services Inc boosted its position in Vertex Pharmaceuticals by 23.7% in the first quarter. Commonwealth Equity Services Inc now owns 6,999 shares of the pharmaceutical company’s stock worth $556,000 after buying an additional 1,342 shares during the last quarter. Virginia Retirement System acquired a new position in Vertex Pharmaceuticals during the first quarter worth about $317,000. Pacad Investment Ltd. acquired a new position in Vertex Pharmaceuticals during the first quarter worth about $715,000. Finally, Ngam Advisors L.P. boosted its position in Vertex Pharmaceuticals by 28.5% in the first quarter. Ngam Advisors L.P. now owns 64,855 shares of the pharmaceutical company’s stock worth $5,155,000 after buying an additional 14,372 shares during the last quarter. Institutional investors own 96.19% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.